Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II
Public ClinicalTrials.gov record NCT00799643. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study will determine whether salicylates represent a new pharmacological option for diabetes management. The study is conducted in two stages. Enrollment in the first stage is complete. The primary objective of the first stage was to select a dose of salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic control. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk.
Study identification
- NCT ID
- NCT00799643
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 638 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2008 (Type not available)
- Primary completion
- Sep 2012 (Actual)
- Completion
- Not listed
- Last update posted
- Dec 11, 2017
Started 2008
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | — | — |
| University of California, San Diego | San Diego | California | — | — |
| Chapel Medical Group | New Haven | Connecticut | — | — |
| Emory University School of Medicine | Atlanta | Georgia | — | — |
| Kaiser Permanente | Tucker | Georgia | — | — |
| Indiana University | Indianapolis | Indiana | — | — |
| Tulane University Health Sciences Center | New Orleans | Louisiana | — | — |
| Medstar Research Institute | Hyattsville | Maryland | — | — |
| Dr. Rudo, Westminster, MD | Westminster | Maryland | 21157 | — |
| Joslin Diabetes Center | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48106 | — |
| Washington University School of Medicine | St Louis | Missouri | — | — |
| University of Nebraska Medical Center | Omaha | Nebraska | — | — |
| North Shore Diabetes and Endocrine Associates | New Hyde Park | New York | — | — |
| Columbia University | New York | New York | — | — |
| Lang Medical Center | Queens | New York | — | — |
| Albert Einstein College of Medicine | The Bronx | New York | — | — |
| Carolina's Health Care | Charlotte | North Carolina | — | — |
| University of North Carolina | Durham | North Carolina | — | — |
| University of Texas Southwestern | Dallas | Texas | — | — |
| Scott and White | Temple | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00799643, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 11, 2017 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00799643 live on ClinicalTrials.gov.